Skyrocketing Demand for 'Miracle' Weight Loss Drugs Leads to Shortages and Rationing

Demand for new weight loss drugs like Ozempic and Mounjaro has skyrocketed, with doctors calling them "miracles" for some patients.

Drugmakers Eli Lilly and Novo Nordisk are racing to expand manufacturing capacity to meet demand.

Lilly is spending $4 billion to double production of drugs like Mounjaro by end of 2023.

Supply issues have led to rationing and hard choices for doctors prescribing the medications.

Approval of Mounjaro for weight loss could further strain supply when decision expected in 2023.